The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee fo (Q35583825)
Jump to navigation
Jump to search
scientific article published on 14 December 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee fo |
scientific article published on 14 December 2010 |
Statements
1 reference
The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee fo (English)
1 reference
Iordanis Gravanis
1 reference
Jens Ersbøll
1 reference
Eva Skovlund
1 reference
Eric Abadie
1 reference
Michel Marty
1 reference
Francesco Pignatti
1 reference
14 December 2010
1 reference
1 reference
15
1 reference
12
1 reference
1335-1343
1 reference
Identifiers
1 reference
1 reference
1 reference